The presence of DNMT3A‐CHIP is associated with a significantly increased risk of heart failure, ischemic stroke, and mortality, with a 1.45‐fold higher prevalence in atrial fibrillation (AF) patients.6 Here, DNMT3A is linked to heart failure.